Preterm Labor Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drugs (Tocolytic Drugs (Beta – Mimetic, Calcium Channel Blockers, NSAIDS), Corticosteroids, Magnesium Sulphate, Antibiotics, Others), By Dosage Form (Tablets, Capsules, Injections), By End User (Hospitals, Pediatric and Neonatal Clinics, Nursing Homes, Pharmacy) and Region Forecast 2020-2031

Preterm Labor Treatment Market size was valued at US$ 995.0 million in 2024 and is expected to reach US$ 1,447.4 million by 2031, growing at a significant CAGR of 5.5% from 2025-2031. The increased number of teen and old-aged pregnancies and increased pregnancy rates of twins, triplets, or other multiples because of IVF and other fertility treatments. Preterm labor treatments include medications to prevent labor contractions in the opening of the cervix after week 20 and before week 37 of pregnancy. The preterm labor induces greater health risks for the baby and mother. According to WHO, 13.4 million babies were born preterm in 2020 and preterm birth complications are the leading cause of death among children under 5 years of age, responsible for approximately 900,000 deaths in 2019. The increased prevalence of genital infections, and chronic conditions such as diabetes, and high blood pressure are the major factors driving the preterm labor treatment market.

Moreover, the increased frequency of issues like shortened cervix, problems with the uterus or placenta, and amniotic fluid infections are blooming the market. Furthermore, the recent discovery of Piezo 1 protein in the muscular layer of the uterus for relaxing the uterus has provided an opportunity for the development of a new target for therapies to treat preterm labor. The changing lifestyle with unhealthy eating habits and drinking and smoking have increased the chances of preterm labor. For instance, according to CDC in 2016, the prevalence of smoking was higher around 18.9% in mothers aged between 20 and 29 and 5.2% in mothers aged between 30 and 34. Based on the drugs, tocolytic drugs are dominating the market owing to the extended delay in labor. For instance, as per the report published by Cochrane in August 2022, tocolytics postpone preterm delivery and give women more time to get medications that can assist a baby to breathe and feed if they are born prematurely, and that reduces the likelihood that the child will have cerebral palsy. But, the changing preference of the population to remain childless or adopt a child rather than undergo a complicated pregnancy is hindering the growth of the preterm labor treatment market. However, growing urbanization, improving healthcare infrastructure, high disposable income, and increased awareness among people regarding pregnancies are leading to the flourishment of the market and are expected to burgeon the market in forecasted years.

Key Developments

• In February 2023, Eylea® (aflibercept) injection of Regeneron Pharmaceuticals, Inc. was approved as the first pharmacologic treatment for preterm infants with retinopathy of prematurity (ROP) by the FDA
• In July 2021, Organon and ObsEva entered a global license agreement to develop and commercialize Ebopiprant (OBE022), an Investigational Agent being evaluated as a first-in-class treatment for preterm labor.